Cardiovascular disorder therapeutic - Ionis Pharmaceuticals/Novartis
Latest Information Update: 21 Aug 2023
At a glance
- Originator Ionis Pharmaceuticals
- Developer Ionis Pharmaceuticals; Novartis
- Class Antisense oligonucleotides; Cardiovascular therapies
- Mechanism of Action Lipoprotein A expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cardiovascular disorders